Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 44 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance Aiming to Prevent Cancer Cases, ESMO Calls Against Misleading Alcohol-Labelling Following European Parliament Vote on the EU Wine Package MOST POPULAR Breast Cancer Centers Rarely Follow National Screening Recommendations, Study Says March 19, 2021 Why ASCO’s Annual Meeting Matters for People With Cancer and How... June 1, 2021 How I Navigated Being a Young Mom During Cancer: A Survivor’s... February 15, 2023 Drug Combo JAKs Up Immunotherapy in Two Clinical Trials August 8, 2024 Load more HOT NEWS Mohs Surgery for Skin Cancer: What to Know and What to... How to Maintain Your Sexual Health During and After Lung Cancer 9 Ways to Use Social Media for Support Throughout Your Cancer... Strict Safety Measures in Austria Results in Low SARS-CoV-2 Detection Rate...
